Cytek Biosciences, Inc. CTKB
5.52 USD -0.24 (-4.17%)
At closeNov 12, 2026, 4:01 PM EST
5.52 0.00 0.00%
After hours · Nov 12, 4:01 PM ET
5.45 Day range 5.69
3.31 52-week range 6.34
- YTD
- +9.31%
- 1 year
- +14.76%
News
benzinga.com Stephens & Co. Maintains Overweight on Cytek Biosciences, Raises Price Target to $7 Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $6 to $7.
globenewswire.com Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug…
seekingalpha.com Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
benzinga.com Cytek Biosciences Q3 2026 Earnings Call Transcript Cytek Biosciences (NASDAQ:CTKB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Cytek Biosciences Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $53.229M Beat $52.800M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 25 percent decrease over losses of…
benzinga.com Cytek Biosciences Narrows FY2026 Sales Guidance from $207.000M-$212.000M to $208.000M-$211.000M vs $209.415M Est Cytek Biosciences (NASDAQ:CTKB) narrows FY2026 sales outlook from $207.000 million-$212.000 million to $208.000 million-$211.000 million vs $209.415 million estimate.- benzinga.com Cytek Biosciences Says Jury Finds In Cytek’s Favor On Three Of Four Asserted Patent Claims; To Challenge Remaining Finding; Jury Awarded Past Damages Consisting Of $20M In Lost Profits And $36M In Royalties Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court
benzinga.com Cytek Biosciences Q2 EPS $(0.09), Inline, Sales $48.140M Miss $48.610M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.04) per share from the same…- benzinga.com Cytek Biosciences Raises FY2026 Sales Guidance from $205.000M-$212.000M to $207.000M-$212.000M vs $208.767M Est Cytek Biosciences (NASDAQ:CTKB) raises FY2026 sales outlook from $205.000 million-$212.000 million to $207.000 million-$212.000 million vs $208.767 million estimate.
benzinga.com Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 results. Other stocks declining in pre-market.
benzinga.com Concrete Pumping Holdings Reports Blowout Q2 Results, Joins ServiceTitan and Other Big Stocks Moving Higher in Friday's Pre-Market Session US stock futures higher, Nasdaq futures down. Concrete Pumping Holdings shares up 28.94% pre-market. Other stocks moving in pre-market.
benzinga.com Braze Posts Mixed Q1 Results, Joins Sidus Space, Everpure And Other Big Stocks Moving Lower In Thursday's Pre-Market Session US stock futures lower, Braze Inc (BRZE) shares drop 8.4% in pre-market trading after reporting mixed Q1 results. Other stocks also down.
benzinga.com Why Phreesia Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket Phreesia (NYSE: PHR) shares rose in pre-market trading after better-than-expected sales results. Other gainers include Snowflake, Genius Group, and Astrotech.- benzinga.com Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75 Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $5.5 to $4.75.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5 Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $6 to $5.5.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Cytek Biosciences Affirms FY2026 Sales Guidance of $205.000M-$212.000M vs $208.235M Est Cytek Biosciences (NASDAQ:CTKB) affirms FY2026 sales outlook from $205.000 million-$212.000 million to $205.000 million-$212.000 million vs $208.235 million estimate.
benzinga.com Cytek Biosciences Q1 EPS $(0.15) Misses $(0.10) Estimate, Sales $44.135M Miss $44.328M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 66.67 percent decrease over losses of…- benzinga.com Cytek Biosciences Sees FY2026 Sales $205.000M-$212.000M vs $207.058M Est Cytek Biosciences (NASDAQ:CTKB) sees FY2026 sales of $205.000 million-$212.000 million vs $207.058 million analyst estimate.
benzinga.com Earnings Breakdown: Cytek Biosciences Q4 - benzinga.com Cytek Biosciences Q4 EPS $(0.34) Misses $(0.02) Estimate, Sales $62.141M Beat $57.187M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.02) by 1378.26 percent. This is a 585.71 percent decrease over…
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Cytek Sees $62M Q4 Revenue Vs $56.99M Est, Forecasts About $201M in Full-Year 2025 Sales Vs $196.71M Est Cytek Biosciences, Inc. (NASDAQ: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31,…
benzinga.com TD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5 TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $4 to $5.
benzinga.com Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - benzinga.com Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5 Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $8 to $7.5.
- benzinga.com Cytek Biosciences Affirms FY2025 Sales Guidance of $196.000M-$205.000M vs $196.252M Est Cytek Biosciences (NASDAQ:CTKB) affirms FY2025 sales outlook from $196.000 million-$205.000 million to $196.000 million-$205.000 million vs $196.252 million estimate.
- benzinga.com Cytek Biosciences Q3 EPS $(0.04) Beats $(0.05) Estimate, Sales $52.293M Beat $51.489M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 500 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com Cytek Biosciences Announces The Relocation Of Its European Headquarters To A New Facility In Amsterdam's Life Sciences District FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc.…
- benzinga.com Cytek Biosciences Narrows FY2025 Sales Guidance from $196.000M-$210.000M to $196.000M-$205.000M vs $198.301M Est Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million to $196.000 million-$205.000 million vs $198.301 million estimate.
benzinga.com Cytek Biosciences Q2 EPS $(0.04), Inline, Sales $45.602M Miss $46.479M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.08) per share from the same…- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock
- benzinga.com Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7 Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $9 to $7.
benzinga.com DHT Holdings Posts Weak Sales, Joins Compass Diversified, Okta And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com Goldman Sachs Maintains Sell on Cytek Biosciences, Lowers Price Target to $3 Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Sell and lowers the price target from $3.5 to $3.
- benzinga.com Cytek Biosciences Lowers FY2025 Sales Guidance from $204.00M-$212.00M to $196.00M-$210.00M vs $204.43M Est Cytek Biosciences (NASDAQ:CTKB) lowers FY2025 sales outlook from $204.00 million-$212.00 million to $196.00 million-$210.00 million vs $204.43 million estimate.
- benzinga.com Cytek Biosciences Q1 EPS $(0.09) Misses $(0.04) Estimate, Sales $51.93M Beat $42.66M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 125 percent. This is a 80 percent decrease over losses of…
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Stephens & Co. Reiterates Overweight on Cytek Biosciences, Maintains $6 Price Target Stephens & Co. analyst Mason Carrico reiterates Cytek Biosciences (NASDAQ:CTKB) with a Overweight and maintains $6 price target.
- benzinga.com Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8 Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $8.5 to $8.
- benzinga.com Cytek Biosciences Sees FY2025 Sales $204.000M-$212.000M vs $219.60M Est Cytek Biosciences (NASDAQ:CTKB) sees FY2025 sales of $204.000 million-$212.000 million vs $219.60 million analyst estimate.
- benzinga.com Cytek Biosciences Q4 EPS $0.07 Beats $0.05 Estimate, Sales $57.48M Miss $59.38M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 75 percent increase over earnings of $0.04…
- benzinga.com Earnings Scheduled For February 27, 2025
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Cytek Anticipates 2024 Revenue Between $200M-$201M, 4% Growth Over 2023; Q4 Revenue Expected At $57M-$58M, 11%-13% Rise from Q3 Amid $1.5M Impact from Stronger USD. Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024.Cytek expects its…
- benzinga.com Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
- benzinga.com Crude Oil Gains 1%; Chicago PMI Falls In December